Pfizer announced this Tuesday (14) that its pill produced against Covid-19 has almost 90% effectiveness in relation to severe cases of the disease. According to the laboratory, the studies also indicate that the drug is effective against the rapid spread of the Ômicron variant.
Last month, the company had disclosed that a study of 1,200 patients found it was 89% effective in preventing hospitalizations or deaths. The new data, however, was based on analyzes with 2,200 people.
read more:
According to the drugmaker, no deaths were recorded among those who received treatment with the experimental drug dubbed paxlovid. Among those who received the placebo, 12 deaths were counted.
Patients who participated in the study and did not receive the placebo, took the pill along with the antiviral ritonavir every 12 hours for five days, soon after the onset of symptoms.
A second early-stage clinical study also showed that treatment with paxlovid was able to reduce hospital admissions by 70% in a group of approximately 600 adults without comorbidities.
Source: Full News
